A Press Release – ARQ197
ArQule Achieves Clinical Milestone in MiT Trial with ARQ 197 Thursday October 2, 8:01 am ET Confirmed tumor response in clear cell sarcoma leads to expanded trial WOBURN, Mass.–(BUSINESS WIRE)–ArQule, Inc. (NASDAQ: ARQL – News) today announced the expansion of its Phase 2 trial with ARQ 197, a proprietary, orally administered small molecule inhibitor of […]